These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25405535)

  • 21. Comparative analysis of RNA-Seq data from brain and blood samples of Parkinson's disease.
    Chatterjee P; Roy D
    Biochem Biophys Res Commun; 2017 Mar; 484(3):557-564. PubMed ID: 28131841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies.
    Lu M; Hu G
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):577-85. PubMed ID: 22126374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease.
    Chen Y; Cai X; Xu R
    AMIA Annu Symp Proc; 2015; 2015():1851-60. PubMed ID: 26958284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
    Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
    PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic metabolic analysis of potential target, therapeutic drug, diagnostic method and animal model applicability in three neurodegenerative diseases.
    Li WX; Li GH; Tong X; Yang PP; Huang JF; Xu L; Dai SX
    Aging (Albany NY); 2020 May; 12(10):9882-9914. PubMed ID: 32461378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R; Merchant KM; Ryan T
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondria: A Therapeutic Target for Parkinson's Disease?
    Luo Y; Hoffer A; Hoffer B; Qi X
    Int J Mol Sci; 2015 Sep; 16(9):20704-30. PubMed ID: 26340618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systems biology approach towards the identification of candidate therapeutic genes and potential biomarkers for Parkinson's disease.
    Sakharkar MK; Kashmir Singh SK; Rajamanickam K; Mohamed Essa M; Yang J; Chidambaram SB
    PLoS One; 2019; 14(9):e0220995. PubMed ID: 31487305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic considerations in the treatment of Parkinson's disease.
    Kurzawski M; Białecka M; Droździk M
    Neurodegener Dis Manag; 2015; 5(1):27-35. PubMed ID: 25711452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research on the molecular mechanism of Seretide treatment to asthma disease.
    Liu ZW; Yue F; Gao FY; Qian YB; Wang RL
    Eur Rev Med Pharmacol Sci; 2012 Nov; 16(12):1701-6. PubMed ID: 23161043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of key pathways and transcription factors related to Parkinson disease in genome wide.
    Zhang B; Xia C; Lin Q; Huang J
    Mol Biol Rep; 2012 Dec; 39(12):10881-7. PubMed ID: 23076523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioinformatics analysis raises candidate genes in blood for early screening of Parkinson's disease.
    Zhang Y; Yao L; Liu W; Li W; Tian C; Wang ZY; Liu D
    Biomed Environ Sci; 2014 Jun; 27(6):462-5. PubMed ID: 24961856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel and functional ABCB1 gene variant in sporadic Parkinson's disease.
    Li Y; Li Y; Pang S; Huang W; Zhang A; Hawley RG; Yan B
    Neurosci Lett; 2014 Apr; 566():61-6. PubMed ID: 24572589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying distinct candidate genes for early Parkinson's disease by analysis of gene expression in whole blood.
    Sun AG; Wang J; Shan YZ; Yu WJ; Li X; Cong CH; Wang X
    Neuro Endocrinol Lett; 2014; 35(5):398-404. PubMed ID: 25275262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging targets and new small molecule therapies in Parkinson's disease treatment.
    Zhang H; Tong R; Bai L; Shi J; Ouyang L
    Bioorg Med Chem; 2016 Apr; 24(7):1419-30. PubMed ID: 26935940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.